According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “
PETX has been the topic of a number of other reports. Barclays PLC lowered their price target on shares of Aratana Therapeutics from $15.00 to $11.00 and set an overweight rating on the stock in a research note on Thursday, August 11th. Jefferies Group initiated coverage on shares of Aratana Therapeutics in a research note on Friday, August 19th. They set a buy rating and a $13.00 price target on the stock. William Blair reissued an outperform rating on shares of Aratana Therapeutics in a research note on Wednesday, August 17th. Lake Street Capital reissued a buy rating and issued a $15.00 price objective on shares of Aratana Therapeutics in a research note on Tuesday, September 6th. Finally, Credit Suisse Group AG reissued a buy rating and issued a $11.00 price objective on shares of Aratana Therapeutics in a research note on Wednesday, August 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. Aratana Therapeutics presently has an average rating of Buy and an average price target of $11.28.
Shares of Aratana Therapeutics (NASDAQ:PETX) opened at 8.91 on Thursday. The firm’s market capitalization is $315.55 million. The firm’s 50 day moving average is $9.24 and its 200-day moving average is $7.55. Aratana Therapeutics has a 12 month low of $2.56 and a 12 month high of $10.73.
Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.37. Aratana Therapeutics had a negative net margin of 166.67% and a negative return on equity of 17.53%. The business had revenue of $38.05 million for the quarter, compared to analysts’ expectations of $15.14 million. During the same period in the prior year, the company posted ($0.23) EPS. On average, analysts expect that Aratana Therapeutics will post ($0.78) EPS for the current fiscal year.
In other news, insider Craig A. Tooman sold 30,000 shares of the stock in a transaction dated Friday, September 9th. The shares were sold at an average price of $9.25, for a total transaction of $277,500.00. Following the transaction, the insider now directly owns 72,424 shares in the company, valued at approximately $669,922. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Ernst Heinen sold 10,000 shares of the stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $10.00, for a total transaction of $100,000.00. Following the transaction, the insider now owns 115,494 shares in the company, valued at $1,154,940. The disclosure for this sale can be found here. 6.70% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in PETX. Algert Global LLC bought a new position in shares of Aratana Therapeutics during the third quarter valued at $221,000. Metropolitan Life Insurance Co. NY bought a new position in shares of Aratana Therapeutics during the second quarter valued at $162,000. First Light Asset Management LLC raised its position in shares of Aratana Therapeutics by 52.9% in the second quarter. First Light Asset Management LLC now owns 684,921 shares of the biopharmaceutical company’s stock valued at $4,329,000 after buying an additional 236,915 shares during the last quarter. A.R.T. Advisors LLC raised its position in shares of Aratana Therapeutics by 81.5% in the second quarter. A.R.T. Advisors LLC now owns 71,515 shares of the biopharmaceutical company’s stock valued at $451,000 after buying an additional 32,111 shares during the last quarter. Finally, Bridgeway Capital Management Inc. raised its position in shares of Aratana Therapeutics by 85.1% in the second quarter. Bridgeway Capital Management Inc. now owns 86,983 shares of the biopharmaceutical company’s stock valued at $550,000 after buying an additional 40,000 shares during the last quarter. Institutional investors and hedge funds own 85.54% of the company’s stock.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.